Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Str., IMED, 66421, Homburg (Saar), Germany.
Clin Res Cardiol. 2017 Jul;106(7):475-484. doi: 10.1007/s00392-017-1095-0. Epub 2017 Mar 22.
Hypertension is the most common chronic cardiovascular condition with increasing prevalence all over the world. Treatment of patients at risk requires a multimodal therapeutic concept to adjust blood pressure, including systematic identification of secondary causes of hypertension or pseudo-resistance, lifestyle modification, polypharmacy, and as well as accompanying risk factors and comorbidities. The present review discusses recent studies on patients with increased cardiovascular risk potentially influencing future treatment strategies. It covers blood pressure targets in patients at risk (SPRINT), novel treatment options such as angiotensin receptor neprilysin inhibitors, discusses the treatment of patients with impaired glucose tolerance, and appreciates novelties in controlling therapy-resistant hypertension by fourth-line pharmacotherapies (PATHWAY), as well as new interventional approaches.
高血压是最常见的慢性心血管疾病,其患病率在全球范围内呈上升趋势。治疗高危患者需要一个多模式的治疗方案来调整血压,包括系统性地识别高血压的继发性原因或假性耐药、生活方式的改变、联合用药,以及伴随的危险因素和合并症。本综述讨论了最近关于增加心血管风险的患者的研究,这些研究可能会影响未来的治疗策略。它涵盖了高危患者的血压目标(SPRINT)、新型治疗选择,如血管紧张素受体脑啡肽酶抑制剂,讨论了治疗糖耐量受损的患者,以及通过四线药物治疗(PATHWAY)控制治疗抵抗性高血压的新方法,以及新的介入方法。